The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months


You May Also Like

The Board of Directors of Orion Corporation decided on an incentive plan for key persons

                                                                         ORION CORPORATION  STOCK EXCHANGE RELEASE    2 FEB 2016  AT 14:45 PM EET               ...

Relievant Announces Publication of Positive Outcomes in 12-Month SMART Sham RCT

SUNNYVALE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Relievant Medsystems, a privately held medical ...